INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Liberator Medical Holdings, Inc. of Commencement of a Class Ac...
November 30 2015 - 12:01PM
The following statement is being issued by Levi & Korsinsky,
LLP:
To: All Persons or Entities who
purchased Liberator Medical Holdings, Inc. (NYSE MKT:LBMH)
stock prior to November 20, 2015.
You are hereby notified that a
class action has been has commenced in Nevada
state court challenging the fairness of the
sale of Liberator Medical Holdings, Inc. to C. R.
Bard, Inc. (NYSE:BCR) for $3.35 in cash per share. The claims stem
from concerns that the Board of Liberator Medical may have breached
their fiduciary duties to stockholders by failing to adequately
shop the Company before agreeing to enter into this transaction,
and that C. R. Bard, Inc. may be underpaying for Liberator Medical
shares. In particular, at least one analyst set a price target of
$8.00 per Liberator Medical share. To learn more about the
investigation and your rights, go to:
http://zlk.9nl.com/liberator-medical-lbmh
or contact Joseph E. Levi, Esq. either via email
at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free:
(877) 363-5972. There is no cost or obligation to
you.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, Connecticut and Washington D.C. The firm’s
attorneys have extensive expertise in prosecuting securities
litigation involving financial fraud, representing investors
throughout the nation in securities lawsuits and have
recovered hundreds of millions of dollars for aggrieved
shareholders. For more information, please feel free to
contact any of the attorneys listed below. Attorney advertising.
Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
Bard C R (NYSE:BCR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bard C R (NYSE:BCR)
Historical Stock Chart
From Mar 2023 to Mar 2024